Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272066 | 0.76 | LMNA (0.51) | POLBGAATYK2MAPTCYP1A2 | |
| SCHEMBL10094168 | 0.75 | GRM5 (0.58) | POLBGAAGRM5MAPT | |
| SCHEMBL29685491 | 0.73 | GAA (0.44) | POLBGAATYK2GRM5MAPT | |
| SCHEMBL10094190 | 0.72 | GRM5 (0.46) | GRM5ASIC3IDH1 | |
| SCHEMBL10094257 | 0.72 | CCNA2 (0.45) | TYK2GRM5 | |
| SCHEMBL29685162 | 0.71 | TP53 (0.47) | POLBGAAGRM5MAPTTP53 | |
| SCHEMBL885037 | 0.71 | KCNA5 (0.46) | POLBGAATYK2GRM5MAPT | |
| SCHEMBL25294012 | 0.70 | POLB (0.44) | POLBGAATYK2GRM5MAPT | |
| SCHEMBL10094191 | 0.70 | DHODH (0.51) | POLBGAAMAPTCYP1A2ABCG2 | |
| SCHEMBL25242188 | 0.70 | TYK2 (0.45) | POLBGAATYK2GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | POLB 4819/4885GAA 3707/4885TYK2 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.